改进区域划分的圆Packing变分算法

通过改进基于Power图的区域划分,提出一种收敛速度更快的圆packing算法.首先固定容器面积,将输入圆缩小一定的倍数,随机撒在容器中;之后对圆心点进行三角化,并根据相邻圆的半径比值对容器进行区域划分;再让所有圆在不超出自己区域边界的条件下尽量等比例增长至最大;最后将划分区域-长大的过程迭代下去,得到最大增长倍数.实验结果表明,该算法能够使得圆packing的过程更快地达到收敛.国家自然科学基金(61472332);;福建省自然科学基金(2018J01104

102例初诊2型糖尿病患者中医病理特点分析

现阶段糖尿病已经成为非传染性的流行病。由于检测手段的先进性和人们健康意识的普遍提高,很多2型糖尿病患者是由于“健康“体检所发现,其临床表现已非传统消渴之“三多一少“所能概括。故运用中医学的研究方法探讨初诊2型糖尿病患者的中医病理特点,就显得尤为必要。本研究对厦门地区初诊2型糖尿病患者进行规范而全面的临床资料收集,运用中医证素辨证的方法,探讨初诊2型糖尿病福建省卫生厅资助课题(WZZZ0903

Preparation of SiBN fiber reinforced SiBN ceramic matrix composites by precursor infiltration-pyrolysis method

连续纤维增强氮化物陶瓷基复合材料是耐高温透波材料的主要发展方向,纤维是目前制约耐高温透波复合材料发展的关键,而SiBN陶瓷纤维是一种兼具耐高温、透波、承载的新型陶瓷纤维。以聚硅氮烷为陶瓷先驱体,以SiBN连续陶瓷纤维为增强体,采用先驱体浸渍-裂解法制备了SiBN陶瓷纤维增强SiBN陶瓷基复合材料,研究了复合材料的热膨胀特性、力学性能、断裂模式以及微观结构。结果表明:SiBN陶瓷纤维增强SiBN陶瓷基复合材料呈现明显的脆性断裂特征,复合材料的弯曲强度和拉伸强度分别为88.52 MPa和6.6 MPa,纤维的力学性能仍有待于提高

非掺半绝缘InP材料的电子辐照缺陷研究

本文针对磷化铁(FeP_2)气氛下高温退火非掺杂半绝缘磷化铟(IP SI-InP)材料,应用正电子寿命谱及热激电流谱学技术,研究了该材料在电子辐照前后的缺陷情况.研究发现,该材料经电子辐照后缺陷浓度在增大,且形成了复合体的缺陷结构,电子辐照后的正电子湮没平均寿命增加了18 ps,对应的热激电流谱(TSC)也出现了相应的缺陷峰.本文还对缺陷的特性、影响材料的性能等进行了简要的论

一种杀生剂耦合生石灰处理污泥的方法

一种杀生剂耦合生石灰处理污泥的方法，属于污泥处理技术领域。污泥中含有大量的微生物絮体，通过添加杀生剂和生石灰破坏菌胶团结构释放内部水，采用压滤技术可以达到污泥深度脱水的目的。采用该方法处理后泥饼含水率为40～60wt.%，满足污泥后续处理要求

植物模式标本的考证与数字化:以中国国家植物标本馆为例

模式标本是最重要的植物标本,是确定植物学名的依据,是植物分类学家从事植物系统分类研究必不可少的科学材料,也是开展专科专属研究、编写国家或地方植物志、进行植物区系调查研究、开发利用和保护植物资源的重要基本资料。但模式标本的人为和自然毁损难以避免,模式标本及其标签信息的数字化使得模式标本的形态、地理分布、采集等主要信息得到最大限度的永久保存,可以极大地方便模式标本信息的共享,可以为科学研究人员或相关人员提供植物形态、地理分布、历史变迁等多方面的信息。本文以中国科学院植物研究所国家植物标本馆维管束植物模式标本数字化建设为例,详细介绍了规范化整理模式标本的方法、模式标本数字化的操作流程,并通过大量实例介绍了模式标本考订的过程、常见问题的处理方法等,以期为其他单位开展模式标本数字化建设提供经验

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials

JUNO Sensitivity on Proton Decay p→νˉK+p\to \bar\nu K^+ Searches

The Jiangmen Underground Neutrino Observatory (JUNO) is a large liquid scintillator detector designed to explore many topics in fundamental physics. In this paper, the potential on searching for proton decay in $p\to \bar\nu K^+$ mode with JUNO is investigated.The kaon and its decay particles feature a clear three-fold coincidence signature that results in a high efficiency for identification. Moreover, the excellent energy resolution of JUNO permits to suppress the sizable background caused by other delayed signals. Based on these advantages, the detection efficiency for the proton decay via $p\to \bar\nu K^+$ is 36.9% with a background level of 0.2 events after 10 years of data taking. The estimated sensitivity based on 200 kton-years exposure is $9.6 \times 10^{33}$ years, competitive with the current best limits on the proton lifetime in this channel